繁體版 / 简体版
 
ABOUT US
/ MILESTONE

MILESTONE

  • 2016

     FB825 completed Phase I clinical trial in USA
    ‧ Microbio and Oneness Biotech co-setup PIC/S GMP plant in Taiwan Nan-Zhou
    ‧ Fountain Biopharma’s “Animal Center” received AAALAC accreditation
    ‧ Established “Sun BioFund Inc.”

  • 2015

    ‧ MB-110 received IND approval from US FDA for Phase I clinical trial
    ‧ OB318 received IND approval from TFDA for Phase I clinical trial
    ‧ ON101 began clinical pharmacokinetic tests
    ‧ Fountain Biopharma Translational Biochemical Analysis Centre certified by TAF technology

  • 2014

    ‧ FB825 received IND approval from US FDA for Phase I clinical trial
    ‧ ON101 received IND approval from Taiwan MOHW for multi-centers clinical trial
    ‧ ON101 received IND approval from Hong Kong DOH for Phase III clinical trial
    ‧ OB318 received IND approval from US FDA for Phase I clinical trial
    ‧ Diamond Biofund Inc. managed the largest “Evergreen Fund” in Taiwan, managing assets of NTD 8 billion
    ‧ Diamond Biofund Inc. initiated investment into Synovel, Sinew Pharma and 3D Global Biotech Inc.
    ‧ Fountain Biopharma setup “Animal Center” for Drug Screening

  • 2013

    ‧ Herbiron received NDA from Taiwan Ministry of Health & Welfare
    ‧ MB-6 began Phase III clinical trial
    ‧ Established “Diamond Biofund Inc.”

  • 2012

    ‧ “Fountain Biopharma Co., Ltd.” Listed on Taiwan Stock Exchange (4159)
    ‧ Established “Diamond Bio Venture” with Fubon Investment and Ruentex, raised NTD 3 billion

  • 2011

    ‧ MS-20 received NDA from Taiwan Ministry of Health & Welfare
    ‧ Established collaboration with Academia Sinica to develop new antibody through glycan engineering

  • 2010

    ‧ Established “Fountain Biopharma Co., Ltd.”, development of monoclonal antibody and protein new drugs
    ‧ Established the world largest fully human monoclonal antibody library
    ‧ GAP Site expansion in GaoXiong for plectranthus amboinicus

  • 2009

    ‧ Oneness Biotech Co., Ltd. listed on Taiwan Stock Exchange (4743)

  • 2008

    ‧ Established “Oneness Biotech Co., Ltd.”, development of botanical new drugs
    ‧ ON101 received Phase II IND approval from US FDA, TFDA and began Phase II clinical trial
    ‧ Herbiron began Phase III clinical trial
    ‧ MB-6 received Phase II IND approval from US FDA, TFDA and began Phase II clinical trial

  • 2006

    ‧ Microbio Co., Ltd. listed on Taiwan Stock Exchange (4128)

  • 2005

    ‧ Established2nd “Long-Tan” GMP Manufacturing Plant

  • 2004

    ‧ Established “Microbio (Shanghai) Co., Ltd.”
    ‧ Awarded “The First Biotech R&D Center in Taiwan” from MOEA

  • 2001

    ‧ Established “Long-Tan” GMP Manufacturing Plant
    ‧ MS-20 began Phase III clinical trial

  • 2000

    ‧ Micobio Co., Ltd. Founded

  • 1997

    ‧ Established of Microbio R&D platform